Sildenafil
Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow. It is used both to treat erectile dysfunction and, at different doses, to lower abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).
Molekularmasse
474,5800 g/mol
LogP
1,50
TPSA
118,00 Ų
Lipinski-Regel der Fünf
Bestanden
Therapeutische Bereiche
Arzneimittelklassen
Wirkmechanismus
Selective PDE5 inhibitor increasing cGMP.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Selective PDE5 inhibitor increasing cGMP.
2D-Struktur
Cite this structure
Embed this structure
SMILES
CCCc1nn(C)c2c(=O)[nH]c(-c3cc(S(=O)(=O)N4CCN(C)CC4)ccc3OCC)nc12
InChI
InChI=1S/C22H30N6O4S/c1-5-7-17-19-20(27(4)25-17)22(29)24-21(23-19)16-14-15(8-9-18(16)32-6-2)33(30,31)28-12-10-26(3)11-13-28/h8-9,14H,5-7,10-13H2,1-4H3,(H,23,24,29)
Molecular Formula
C22H30N6O4S
HBD / HBA
1 / 8
Rotierbare Bindungen
7
Schwere Atome
33
Combining tamsulosin (alpha-1 blocker) with sildenafil (PDE-5 inhibitor) produces additive vasodilation, substantially increasing the risk of symptomatic hypotension, dizziness, and syncope.
Combining sildenafil with nitrates causes profound, potentially fatal hypotension; this combination is absolutely contraindicated.
No side effects recorded
Side effect data is not yet available for this drug.
Häufig gestellte Fragen
Originally developed for heart conditions, this medication relaxes and widens blood vessels by blocking an enzyme called PDE5, increasing blood flow. It is used both to treat erectile dysfunction and, at different doses, to lower abnormally high blood pressure in the arteries of the lungs (pulmonary arterial hypertension).
Selective PDE5 inhibitor increasing cGMP.
Key pharmacokinetic parameters for Sildenafil: Half-life: 4 hours.
Yes, Sildenafil is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
Related Drugs
Same Drug Class
Same Target
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL192. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 135398744. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.
Medizinischer Haftungsausschluss
This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="sildenafil"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/sildenafil/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/sildenafil/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/sildenafil/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="sildenafil"></drugfyi-drug>